1. CARA The Marijuana Stock Chart: http://schrts.co/7lhgFo Information obtained from the internet: CARA is in the medical Marijuana business. Cara is testing CR845 for a pair of treatments. First, Phase III trials are underway for post-surgical pain. Trial results should be released in early 2017, which would serve as a strong catalyst for shares. Second, this drug is in Phase II trials for the treatment of uremic pruritus, a severe itching and pain problem caused by late stage kidney failure. There are approximately 400,000 patients in the U.S. that undergo dialysis, and roughly half of them experience pruritus. As CR845 has undergone larger and larger tests, it has become apparent that this drug has almost no side effects. Around 6% or 7% of people experience dizziness or headaches, which usually fade pretty quickly.
WARNING CARA IS a speculative stock : Investors should also know the financial risk inherent in a drug developer like Cara. The company is burning through $10 million per quarter as it amps up its research efforts and has less than $100 million in the bank. So Cara may need to line up a strong strategic partner or sell more shares before it can successfully launch CR-485. But that’s par for the course among early-stage biotech firms. With so much ground-breaking research being done with both cannabis and opiate-based drugs, Cara should have no trouble finding financial backers when the time comes.
2. NXOPF The Technology Stock Chart: https://www.barchart.com/stocks/quotes/NXOPF " In less than 60 days, a new technology will be revealed that could potentially change an entire industry worth billions of dollars.
In fact, this technology could forever rewrite thousands of years of collective knowledge.
It’s so disruptive that I bet some of the world’s biggest companies – the Apples and Googles of the world – will be jumping at the chance to acquire this patent-pending technology when it’s revealed.
It’s clear that despite all of the improvements smartphone makers have made, the biggest hurdle they have is making a smartphone capable of taking pictures with better magnification.
That’s because no matter the improvements in software, such as higher megapixels or better image processing, the image can only be as good as the source capturing it: the lens system.
Now the basic concept of lens physics revolves around using curved lenses. It tells us that if we want to see further, we need to go longer because the light has to converge into a focus point.
That’s why Apple had to add a second lens system to accommodate those who want to capture pictures from far away.
But what if we are wrong?
What if a curved lens or curved mirrors are not the only way to gather and focus light to retain an image?
What if there was another way?
Folks NexOptic Technology NXOPF has found .......The Other Way!
NexOptic Technology Corp. has an option to acquire 100% of Spectrum Optix, a Company developing technologies relating to imagery and light concentration applications.
Spectrum’s core technology, the patent-pending Blade Optics™, contains flat lenses and aims to disrupt conventional lens and image capture-based systems.
This includes everything from telescopes to cameras and mobile devices, by creating a lens system that reduces the depth (relative to aperture size) currently required in many traditional curved lens stacks.
To make it simple Blade Optics has the ability to manufacture "SMALLER" Optical products which include telescopes, smart phone cameras , optical medical devices and an endless list of other applications!
Folks think about it companies like Google , Apple and Samsung could soon be knocking on NexOptic's door, all clamoring for this new technology!
"WARNING" Folks NXOPF Is a HIGH RISK , HIGH REWARD Stock ! No guts No Glory!
There are always risks to investing.
Earlier last year, the biggest risk for NexOptic was the question of “does the technology work?”
The Company has already announced that its prototype works – it just hasn’t been revealed to the world.
So that means the tech has already been significantly de-risked from that standpoint.
The next most obvious risk in my opinion is PATENT RISK!
NexOptic has already been granted a design patent in Europe and filed a full patent application last year.
In February, its secret technology will be revealed to the world. Given how disruptive it could be, there is a chance someone will challenge it. Challenges to patents are a very normal occurrence for the patent process."
So what else can I say? .........ya puts your money down, and ya takes your chances!
NexOptic has very high-powered patent attorneys on its side and its management is confident they can protect the patent. But until a patent is granted, the risk remains!